Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
2010 1
2011 1
2013 2
2018 1
2019 2
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need.
Azizi M, Cheriyan SK, Peyton CC, Foerster B, Shariat SF, Spiess PE. Azizi M, et al. Curr Treat Options Oncol. 2019 Apr 1;20(5):40. doi: 10.1007/s11864-019-0637-2. Curr Treat Options Oncol. 2019. PMID: 30937554 Review.
Upper tract urothelial carcinoma (UTUC) is a rare genitourinary entity of the renal pelvis and the ureter characterized by a more aggressive disease phenotype when compared with urothelial carcinoma of the bladder (UCB) with more t …
Upper tract urothelial carcinoma (UTUC) is a rare genitourinary entity of the renal pelvis and the ureter …
Diagnosis and management of urothelial carcinoma of the bladder.
Tanaka MF, Sonpavde G. Tanaka MF, et al. Postgrad Med. 2011 May;123(3):43-55. doi: 10.3810/pgm.2011.05.2283. Postgrad Med. 2011. PMID: 21566415 Review.
More than 90% of bladder carcinomas are classified as urothelial carcinoma (UC), which arise from the urothelium. This epithelium, also known as transitional cell epithelium, lines the urinary tract, which extends from the renal pelvis th …
More than 90% of bladder carcinomas are classified as urothelial carcinoma (UC), which arise from the urothelium. This epithel …
The role of systemic chemotherapy in management of upper tract urothelial cancer.
Gayed BA, Thoreson GR, Margulis V. Gayed BA, et al. Curr Urol Rep. 2013 Apr;14(2):94-101. doi: 10.1007/s11934-013-0307-z. Curr Urol Rep. 2013. PMID: 23344684 Review.
Upper tract urothelial cancer (UTUC) accounts for roughly 5 % of all urothelial cancers. ...Extrapolating evidence obtained from experience with multi-modal therapy of patients with urothelial bladder cancer, additional improvements in oncological outc …
Upper tract urothelial cancer (UTUC) accounts for roughly 5 % of all urothelial cancers. ...Extrapolating evidence obtained fr …
Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
Nishiyama N, Kita Y, Ito K, Kato M, Hatakeyama S, Matsushita Y, Naito S, Miyake M, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Nishiyama H, Kobayashi T, Kitamura H; Japan Urological Oncology Group. Nishiyama N, et al. Anticancer Res. 2023 Nov;43(11):5041-5050. doi: 10.21873/anticanres.16703. Anticancer Res. 2023. PMID: 37909969
BACKGROUND/AIM: To evaluate the difference in the clinical efficacy and safety of pembrolizumab between patients with metastatic upper tract urothelial carcinoma (UTUC), which includes renal pelvic urothelial carcinoma (UC) and ureteral U …
BACKGROUND/AIM: To evaluate the difference in the clinical efficacy and safety of pembrolizumab between patients with metastatic uppe …
Current Evidence and Future Perspectives in the Management of Nonmetastatic Upper Tract Urothelial Carcinoma.
Lenfant L, Breda A, Xylinas E, Babjuk M, Moschini M, Rouprêt M; EAU Section of Oncological Urology (ESOU) Board. Lenfant L, et al. Eur Urol Oncol. 2022 Aug;5(4):464-471. doi: 10.1016/j.euo.2021.09.002. Epub 2021 Sep 22. Eur Urol Oncol. 2022. PMID: 34561205
His urine cytology was benign, and computed tomography (CT) with nephrographic phase revealed a 2.5 cm filling defect within the left renal pelvis and luminal narrowing in the right proximal ureter with hydronephrosis. CT showed no lymphadenopathy and no sign …
His urine cytology was benign, and computed tomography (CT) with nephrographic phase revealed a 2.5 cm filling defect within the left ren …
Optimal management of recurrent and metastatic upper tract urothelial carcinoma: Implications of intensity modulated radiation therapy.
Kim MS, Koom WS, Cho JH, Kim SY, Lee IJ. Kim MS, et al. Radiat Oncol. 2022 Mar 9;17(1):51. doi: 10.1186/s13014-022-02020-7. Radiat Oncol. 2022. PMID: 35264197 Free PMC article.
BACKGROUND: Upper tract urothelial carcinoma (UTUC) is rare and the treatment for recurrent or metastatic UTUC is unclear. ...Disease status at RT included initially diagnosed advanced disease (n = 8, 4.6%), local recurrence only (n = 56, 32.2%), distant meta …
BACKGROUND: Upper tract urothelial carcinoma (UTUC) is rare and the treatment for recurrent or metastatic UTUC is uncle …
The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC).
Audenet F, Yates DR, Cussenot O, Rouprêt M. Audenet F, et al. Urol Oncol. 2013 May;31(4):407-13. doi: 10.1016/j.urolonc.2010.07.016. Epub 2010 Sep 29. Urol Oncol. 2013. PMID: 20884249 Review.
OBJECTIVE: Urothelial cell carcinoma of the upper urinary tract (UUT-UCC) is a rare, aggressive urologic cancer with a propensity for multifocality, local recurrence, and metastasis. This review highlights the main chemotherapy regimens available for UUT-UCCs …
OBJECTIVE: Urothelial cell carcinoma of the upper urinary tract (UUT-UCC) is a rare, aggressive urologic cancer with a …
Treatment utilization and overall survival in patients receiving radical nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma: evaluation of updated treatment guidelines.
Upfill-Brown A, Lenis AT, Faiena I, Salmasi AH, Johnson DC, Pooli A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K. Upfill-Brown A, et al. World J Urol. 2019 Jun;37(6):1157-1164. doi: 10.1007/s00345-018-2506-1. Epub 2018 Sep 28. World J Urol. 2019. PMID: 30267197 Free PMC article.
PURPOSE: While radical nephroureterectomy (RNU) is the gold standard treatment for upper tract urothelial carcinoma (UTUC), select patients may benefit from endoscopic treatment (ET). ...To inform the utility of ET, we compare the overall survival (OS) of patients r …
PURPOSE: While radical nephroureterectomy (RNU) is the gold standard treatment for upper tract urothelial carcinoma (UTUC), se …
Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer.
Igawa M, Ohkuchi T, Ueki T, Ueda M, Okada K, Usui T. Igawa M, et al. J Urol. 1990 Sep;144(3):662-5. doi: 10.1016/s0022-5347(17)39548-4. J Urol. 1990. PMID: 2388322
Methotrexate, vinblastine, doxorubicin and cisplatin were used to treat 66 patients with advanced urothelial cancer. Of these 66 patients 58 could be evaluated for response. A total of 84 sites was evaluated in these patients. Response rates were 73% in the bladder, 67% in …
Methotrexate, vinblastine, doxorubicin and cisplatin were used to treat 66 patients with advanced urothelial cancer. Of these 66 pati …